← Back to Search

Imaging Techniques for Multiple Sclerosis

Phase 2
Waitlist Available
Led By Burcu Zeydan, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 days
Awards & highlights

Study Summary

This trial tests if MRI + PET/CT scans can help diagnose MS & measure brain inflammation related to it.

Who is the study for?
This trial is for individuals with Multiple Sclerosis (MS) who are already part of certain MS studies or clinics, and healthy controls without inflammatory brain diseases. Participants must be able to lie still for imaging procedures and give consent. Pregnant or breastfeeding women, recent steroid users, and those with MRI safety risks like pacemakers can't join.Check my eligibility
What is being tested?
The study is testing the effectiveness of combining MRI scans with PET/CT imaging using C-11 ER176 Radiotracer and C11 Pittsburgh Compound B to measure brain inflammation in people with MS.See study design
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort from lying still during imaging, allergic reactions to radiotracers, and exposure to radiation from PET/CT scans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Uptake of C-11 ER176 Radiotracer
Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin
Secondary outcome measures
Number of subjects with adverse events

Trial Design

2Treatment groups
Experimental Treatment
Group I: Multiple Sclerosis GroupExperimental Treatment4 Interventions
Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB & C-11 ER176
Group II: Healthy Control GroupExperimental Treatment4 Interventions
Subjects without inflammatory-demyelinating diseases of the central nervous system
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~1370
PET/CT scan
2013
Completed Phase 1
~340

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,242 Previous Clinical Trials
3,773,284 Total Patients Enrolled
11 Trials studying Multiple Sclerosis
2,039 Patients Enrolled for Multiple Sclerosis
Burcu Zeydan, MDPrincipal InvestigatorMayo Clinic

Media Library

Healthy Control Group Clinical Trial Eligibility Overview. Trial Name: NCT05805839 — Phase 2
Multiple Sclerosis Clinical Trial 2023: Healthy Control Group Highlights & Side Effects. Trial Name: NCT05805839 — Phase 2
Multiple Sclerosis Research Study Groups: Healthy Control Group, Multiple Sclerosis Group
Healthy Control Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05805839 — Phase 2
~95 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top